Last CNY16.61 CNY
Change Today -0.18 / -1.07%
Volume 6.5M
As of 2:05 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

tianjin zhong xin pharm co-a (600329) Snapshot

Open
CNY16.80
Previous Close
CNY16.79
Day High
CNY16.86
Day Low
CNY16.33
52 Week High
01/26/15 - CNY17.03
52 Week Low
03/11/14 - CNY11.55
Market Cap
10.1B
Average Volume 10 Days
10.5M
EPS TTM
CNY0.51
Shares Outstanding
539.3M
EX-Date
07/15/14
P/E TM
32.9x
Dividend
CNY0.05
Dividend Yield
0.30%
Current Stock Chart for TIANJIN ZHONG XIN PHARM CO-A (600329)

Related News

No related news articles were found.

tianjin zhong xin pharm co-a (600329) Related Businessweek News

No Related Businessweek News Found

tianjin zhong xin pharm co-a (600329) Details

Tianjin Zhongxin Pharmaceutical Group Corporation Limited, an investment holding company, produces and sells traditional Chinese medicines, western medicines, and healthcare products primarily in the People's Republic of China. It offers Chinese patent medicines, Chinese medicinal materials, pharmaceutical raw materials and western medicines, bioengineering drugs, nutritious and health products, etc. The company’s principal products include Suxiao Jiuxin Wan, Huoxiang Zhengqi Ruan Jiaonang, Zilong Jin Pian, Jinqi Jiangtang Pian, Weichang An Wan, Biqi Jiaonang, a-2b Interferon, Gliclazide, Te Zi She Fu, etc. It is also involved in the wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products. In addition, the company sells medicinal products under its own brand and other brands to wholesalers. Tianjin Zhongxin Pharmaceutical Group Corporation Limited was founded in 1992 and is based in Tianjin, China.

Founded in 1992

tianjin zhong xin pharm co-a (600329) Top Compensated Officers

Executive Chairman, General Manager and Chair...
Total Annual Compensation: CNY1.0M
Chief Financial Officer
Total Annual Compensation: CNY500.0K
Executive Director
Total Annual Compensation: CNY757.3K
Chief Engineer, Deputy General Manager, Execu...
Total Annual Compensation: CNY500.0K
Compensation as of Fiscal Year 2013.

tianjin zhong xin pharm co-a (600329) Key Developments

Tianjin Zhong Xin Pharmaceutical Group Approves the Resignation of Sun Jun from Position of Deputy General Manager

Tianjin Zhong Xin Pharmaceutical Group at its directorate meeting of 2014 held on November 13, 2014, approved the proposal of agreeing Sun Jun's resignation from position of Deputy General Manager, due to work change.

Tianjin Zhongxin Pharmaceutical Group Announces Cessation of Mr. Sun Jun, Chief Accountant

Tianjin Zhongxin Pharmaceutical Group Corporation Limited announced the cessation of Mr. Sun Jun, Chief Accountant, effective Nov. 13, 2014, due to job assignment change.

Tianjin Zhongxin Pharmaceutical Group Announces Cessation of Mr. Jiao Yan, Deputy General Manager

Tianjin Zhongxin Pharmaceutical Group Corporation Limited announced the cessation of Mr. Jiao Yan, Deputy General Manager, effective Nov. 13, 2014, due to job assignment change.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600329:CH CNY16.61 CNY -0.18

600329 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Oriental Bioengineering Inc $2.00 USD 0.00
View Industry Companies
 

Industry Analysis

600329

Industry Average

Valuation 600329 Industry Range
Price/Earnings 32.7x
Price/Sales 1.8x
Price/Book 4.6x
Price/Cash Flow 24.0x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANJIN ZHONG XIN PHARM CO-A, please visit www.zhongxinp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.